Health Condition 1: - Health Condition 2: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: INTRAVENOUS HALOPERIDOL: DOSE minimum 1mg to maximum 4 mg. MODE OF ADMINISTRATION Intravenous. FREQUENCY OF ADMINSTRATION 0 minutes, 15 minutes, 30 minutes, 45 minutes. People diagnosed
Sponsors
Cancer Institute WIA
Eligibility
Inclusion criteria
Inclusion criteria: 1)All patients who are diagnosed with abdominal cancer and, head and neck cancer, receiving morphine for pain management, in acute severe pain NRS = 7 2)Age 18 – 65 years
Exclusion criteria
Exclusion criteria: 1)People who are already on psychiatric medications or previous psychiatric disorder 2)People in acute delirium or mentally incapacitated or has severe emotional or psychiatric disorder. 3)People with history or current evidence of QT prolongation arrythmia or existing cardiovascular problems 4)People with extrapyramidal symptoms or existing parkinsonism 5)People who are hypotensive, hypothyroid, increased liver function tests 6)People who are allergic to haloperidol 7)People not consenting for the study or inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the effect of intravenous haloperidol as an adjuvant analgesic in treating acute cancer pain among patients visiting the Palliative care Outpatient Department.Timepoint: numerical rating scale will be assessed for pain at 0 minutes, 15 minutes, 30 minutes, 45 minutes and at the end of 1 hour | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the patient reported onset and duration of response to intravenous haloperidol. 2. To determine the dose of haloperidol to attain adequate analgesia. 3. To observe the side effects of administration of intravenous haloperidol 4. To assess the feasibility of performing the study in the palliative care outpatient department Timepoint: within 2 days of intervention | — |
Countries
India
Contacts
Public ContactDr S Rathipriya
Cancer Institute WIA Adyar
Outcome results
None listed